CO7170182A2 - Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos - Google Patents
Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismosInfo
- Publication number
- CO7170182A2 CO7170182A2 CO14240045A CO14240045A CO7170182A2 CO 7170182 A2 CO7170182 A2 CO 7170182A2 CO 14240045 A CO14240045 A CO 14240045A CO 14240045 A CO14240045 A CO 14240045A CO 7170182 A2 CO7170182 A2 CO 7170182A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- polymorphic forms
- difluoropropinamide
- derivatives
- bardoxolone methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C255/47—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of rings being part of condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261687669P | 2012-04-27 | 2012-04-27 | |
| US201361775288P | 2013-03-08 | 2013-03-08 | |
| US201361780444P | 2013-03-13 | 2013-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO7170182A2 true CO7170182A2 (es) | 2015-01-28 |
Family
ID=49483867
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO14240045A CO7170182A2 (es) | 2012-04-27 | 2014-10-29 | Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos |
Country Status (40)
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8129429B2 (en) | 2008-01-11 | 2012-03-06 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| LT2276493T (lt) | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals, Inc. | Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17 |
| RS56795B1 (sr) | 2010-12-17 | 2018-04-30 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| TW201348245A (zh) | 2012-04-27 | 2013-12-01 | Reata Pharmaceuticals Inc | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２－二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013188818A1 (en) | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| MX366913B (es) | 2012-09-10 | 2019-07-30 | Reata Pharmaceuticals Inc | Derivados de c17-alcanodiilo y alquenodiilo de ácido oleanólico y métodos de uso de los mismos. |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| UY39092A (es) | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| WO2016070063A1 (en) | 2014-10-31 | 2016-05-06 | The Regents Of The University Of California | Compositions and methods for treating hiv-associated cognitive dysfunction |
| WO2016130927A1 (en) | 2015-02-12 | 2016-08-18 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| JP7074674B2 (ja) | 2015-09-23 | 2022-05-24 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体 |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
| SG11202011502VA (en) | 2018-05-24 | 2020-12-30 | Renibus Therapeutics Inc | Methods of treating patients at risk for renal injury and renal failure |
| CN119552120A (zh) | 2018-06-15 | 2025-03-04 | 里亚塔医药公司 | 用于抑制IL-17和RORγ的吡唑和咪唑化合物 |
| WO2019246461A1 (en) | 2018-06-20 | 2019-12-26 | Reata Pharmaceuticals, Inc. | Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith |
| PT3833662T (pt) | 2018-08-20 | 2024-03-18 | Janssen Pharmaceutica Nv | Inibidores da interação proteína-proteína keap1-nrf2 |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| EP3956342A4 (en) | 2019-02-15 | 2023-05-24 | Triterpenoid Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR INHIBITION OF NLRP3 INFLAMMASOME AND/OR LON PROTEASE |
| TWI861163B (zh) | 2019-07-19 | 2024-11-11 | 美商瑞塔醫藥有限責任公司 | C17經極性取代之雜芳合成三萜類化合物及其使用方法 |
| CA3163745A1 (en) * | 2019-12-03 | 2021-06-10 | Baylor College Of Medicine | Therapeutic compounds for methods of use in insulin resistance |
| BR112022014660A2 (pt) | 2020-01-24 | 2022-09-13 | Tvardi Therapeutics Inc | Compostos terapêuticos, formulações e usos dos mesmos |
| AU2021397631A1 (en) | 2020-12-11 | 2023-07-20 | Reata Pharmaceuticals Holdings, LLC | Synthetic triterpenoids for use in therapy |
| JP2024504637A (ja) * | 2021-01-18 | 2024-02-01 | リアタ ファーマシューティカルズ インコーポレイテッド | 合成ウルソール酸誘導体及びその使用方法 |
| CN113197905B (zh) * | 2021-04-23 | 2022-04-19 | 浙江大学 | 三萜类化合物在制备神经母细胞瘤治疗药物中的应用 |
| CN113358627B (zh) * | 2021-06-23 | 2022-07-01 | 华中农业大学 | 一种基于拉曼检测的田间快速测定茶树品质成分的方法 |
| CN114344308A (zh) * | 2021-12-22 | 2022-04-15 | 山西医科大学第二医院 | 甲基巴多索隆在制备防治骨关节炎的药物中的应用 |
| CN117050134A (zh) * | 2022-05-05 | 2023-11-14 | 中国科学院上海有机化学研究所 | 酰胺化合物的合成及其用途 |
| WO2023244946A1 (en) | 2022-06-15 | 2023-12-21 | Tvardi Therapeutics, Inc. | Prodrugs of stat3 inhibitors |
| CN115165838B (zh) * | 2022-06-23 | 2025-09-30 | 中国医学科学院血液病医院(中国医学科学院血液学研究所) | 基于拉曼光谱和血清代谢构建mds和aml鉴别模型的方法和试剂盒 |
| EP4349847A1 (en) | 2022-09-21 | 2024-04-10 | Sicor Società Italiana Corticosteroidi S.r.l. | Process and intermediates for preparation of omaveloxolone and salts thereof |
| WO2025029691A1 (en) | 2023-07-28 | 2025-02-06 | Reata Pharmaceuticals Holdings, LLC | Methods for producing triterpenoid derivatives |
| CN117964678A (zh) * | 2024-01-29 | 2024-05-03 | 烟台大学 | C17位杂芳族羰基修饰的齐墩果烷三萜衍生物及其制备方法和用途 |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5555153Y2 (enExample) | 1975-03-19 | 1980-12-20 | ||
| NZ191586A (en) | 1978-10-10 | 1981-10-19 | Sterling Drug Inc | Cyanoketones derived from glycyrrhetinic acid and pharmaceutical compositions |
| US4395423A (en) | 1978-10-10 | 1983-07-26 | Sterling Drug Inc. | Polycyclic cyanoketones |
| US5064823A (en) | 1988-08-24 | 1991-11-12 | Research Triangle Institute | Pentacyclic triterpenoid compounds as topoisomerase inhibitors or cell differentiation inducers |
| US6025395A (en) | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| US6326507B1 (en) | 1998-06-19 | 2001-12-04 | Trustees Of Dartmouth College | Therapeutic compounds and methods of use |
| US6369101B1 (en) | 1999-02-26 | 2002-04-09 | Regents Of The University Of Minnesota | Therapeutic method to treat herpes virus infection |
| ATE449754T1 (de) | 1999-05-14 | 2009-12-15 | Nereus Pharmaceuticals Inc | Interleukin-1 und tumornekrosefaktor-alpha modulatoren,synthese dieser modulatoren und methoden zur anwendung dieser modulatoren |
| US6649654B1 (en) | 1999-11-23 | 2003-11-18 | The Regents Of The University Of California | Methods for identifying and using IKK inhibitors |
| JP2001240573A (ja) | 2000-03-01 | 2001-09-04 | Meiji Seika Kaisha Ltd | トリテルペン誘導体及び肝疾患治療剤 |
| WO2002003996A1 (en) | 2000-07-12 | 2002-01-17 | RAJKUMAR, Sujatha | Use of dammarane-type tritepenoid saporins |
| US6689767B2 (en) | 2000-09-29 | 2004-02-10 | Regents Of The University Of Minnesota | Triterpenes having antibacterial activity |
| US6951847B2 (en) | 2000-09-29 | 2005-10-04 | Regents Of The University Of Minnesota | Methods of treating fungal infections using lupeol |
| AU2001294953A1 (en) | 2000-09-29 | 2002-04-08 | Regents Of The University Of Minnesota | Triterpenes having fungicidal activity against yeast |
| US6878751B1 (en) | 2000-10-19 | 2005-04-12 | Imperial College Of Science Technology And Medicine | Administration of resveratrol to treat inflammatory respiratory disorders |
| CA2430454A1 (en) | 2000-11-28 | 2002-06-20 | Board Of Regents, The University Of Texas System | Cddo-compounds and combination therapies thereof |
| US7435755B2 (en) | 2000-11-28 | 2008-10-14 | The Trustees Of Dartmouth College | CDDO-compounds and combination therapies thereof |
| US20040234977A1 (en) | 2001-05-14 | 2004-11-25 | Da-Wei Gong | Novel alanine transaminase enzyme and methods of use |
| DK1465615T3 (da) | 2002-01-15 | 2012-11-12 | Dartmouth College | Tricykliske bisenonderivater og fremgangsmåder til anvendelse heraf |
| DE60325329D1 (de) | 2002-01-18 | 2009-01-29 | Univ Minnesota | Quaternäre terpensalze als biologisch aktive tenside |
| JP2006515859A (ja) * | 2002-05-13 | 2006-06-08 | トラスティーズ オブ ダートマス カレッジ | 阻害剤およびその使用法 |
| WO2004089357A2 (en) | 2003-04-02 | 2004-10-21 | Regents Of The University Of Minnesota | Anti-fungal formulation of triterpene and essential oil |
| WO2006029221A2 (en) | 2004-09-07 | 2006-03-16 | Pacific Arrow Limited | Anti-tumor compounds with angeloyl groups |
| WO2005042002A2 (en) | 2003-10-30 | 2005-05-12 | Entelos, Inc. | Treatment of rhematoid arthritis with flip antagonists |
| US8288439B2 (en) | 2003-11-04 | 2012-10-16 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods and compositions for the inhibition of HIV-1 replication |
| US20060258752A1 (en) | 2004-02-12 | 2006-11-16 | Vander Jagt David L | Method and compounds for cancer treatment utilizing NFkB as a direct or ultimate target for small molecule inhibitors |
| JP2005314381A (ja) | 2004-03-30 | 2005-11-10 | Anges Mg Inc | 増殖性腎疾患の予防・治療・改善剤 |
| CA2614110A1 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Compositions and methods for the treatment or prevention of disorders relating to oxidative stress |
| JP2009530405A (ja) | 2006-03-23 | 2009-08-27 | アドバンスト ライフ サイエンシズ インコーポレイテッド | 合成五環性トリテルペノイド、ならびにベツリン酸およびベツリンの誘導体 |
| WO2007127791A2 (en) | 2006-04-25 | 2007-11-08 | The Administrators Of The Tulane Educational Fund | New pharmacological method for treatment of neuropathic pain |
| WO2008000068A1 (en) | 2006-06-27 | 2008-01-03 | Wellington Laboratories Inc. | Method for preparing 2-iodo triterpenoid compounds |
| WO2008016095A1 (en) | 2006-08-02 | 2008-02-07 | Santen Pharmaceutical Co., Ltd. | PREVENTIVE OR REMEDY FOR KERATOCONJUNCTIVAL DISORDERS CONTAINING Nrf2 ACTIVATOR AS THE ACTIVE INGREDIENT |
| JP2008110962A (ja) | 2006-08-02 | 2008-05-15 | Santen Pharmaceut Co Ltd | Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤 |
| EP2094651A1 (en) | 2006-11-17 | 2009-09-02 | Trustees Of Dartmouth College | Synthesis and biological activities of new tricyclic-bis-enones (tbes) |
| WO2008064132A2 (en) | 2006-11-17 | 2008-05-29 | Trustees Of Dartmouth College | Synthetic triterpenoids and tricyclic-bis-enones for use in stimulating bone and cartilage growth |
| ES2916604T1 (es) | 2007-02-08 | 2022-07-04 | Biogen Ma Inc | Ensayos de detección de nrf2 y métodos y composiciones relacionados |
| WO2008111497A1 (ja) | 2007-03-08 | 2008-09-18 | Santen Pharmaceutical Co., Ltd. | トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤 |
| US20080254055A1 (en) | 2007-04-11 | 2008-10-16 | John Erich Oblong | Compositions for Regulation of Hair Growth |
| WO2008136838A1 (en) | 2007-05-04 | 2008-11-13 | Trustees Of Dartmouth College | Novel amide derivatives of cddo and methods of use thereof |
| US8088824B2 (en) | 2007-08-15 | 2012-01-03 | Reata Pharmaceuticals Inc. | Forms of CDDO methyl ester |
| WO2009023845A2 (en) | 2007-08-15 | 2009-02-19 | The Board Of Regents Of The University Of Texas System | Combination therapy with synthetic triterpenoids and gemcitabine |
| WO2009058849A1 (en) | 2007-10-29 | 2009-05-07 | University Of Rochester | Use of electrophilic compounds for inducing platelet production or maintaining platelet function |
| US8129429B2 (en) | 2008-01-11 | 2012-03-06 | Reata Pharmaceuticals, Inc. | Synthetic triterpenoids and methods of use in the treatment of disease |
| TW201006474A (en) | 2008-04-18 | 2010-02-16 | Reata Pharmaceuticals Inc | Natural products including an anti-flammatory pharmacore and methods of use |
| TW201004627A (en) | 2008-04-18 | 2010-02-01 | Reata Pharmaceuticals Inc | Antioxidant inflammation modulators: novel derivatives of oleanolic acid |
| NZ588711A (en) | 2008-04-18 | 2012-10-26 | Reata Pharmaceuticals Inc | C-17 homologated oleanolic acid derivatives for treating cancer |
| BRPI0911208B1 (pt) | 2008-04-18 | 2021-05-25 | Reata Pharmaceuticals, Inc | Compostos moduladores inflamatórios antioxidantes, seu uso, e composição farmacêutica |
| LT2276493T (lt) * | 2008-04-18 | 2019-01-10 | Reata Pharmaceuticals, Inc. | Antioksidaciniai uždegimo moduliatoriai: oleanolio rūgšties dariniai su amino ir kitomis modifikacijomis c-17 |
| JP5758801B2 (ja) | 2008-07-22 | 2015-08-05 | トラスティーズ・オブ・ダートマス・カレッジＴｒｕｓｔｅｅｓ ｏｆ Ｄａｒｔｍｏｕｔｈ Ｃｏｌｌｅｇｅ | 単環式シアノエノンおよびその使用方法説明 |
| US8778990B2 (en) | 2008-11-04 | 2014-07-15 | Trustees Of Dartmouth College | Betulinic acid derivatives and methods of use thereof |
| EP2362770A4 (en) | 2008-11-21 | 2012-05-30 | Univ Johns Hopkins | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING RADIATION DAMAGE |
| LT3254675T (lt) | 2009-02-13 | 2019-06-25 | Reata Pharmaceuticals, Inc. | Sulėtinto atpalaidavimo peroralinio vartojimo kompozicijos, kurių sudėtyje yra amorfinis cddo-me |
| JP2012525415A (ja) | 2009-05-01 | 2012-10-22 | オプソテツク・コーポレイシヨン | 眼科疾患を処置または予防するための方法 |
| LT2558105T (lt) | 2010-04-12 | 2020-02-10 | Reata Pharmaceuticals, Inc. | Bardoksolono metilas, skirtas nutukimo gydymui |
| WO2011140078A1 (en) | 2010-05-04 | 2011-11-10 | Concert Pharmaceuticals, Inc. | Synthetic triterpenoid derivatives |
| WO2012009171A2 (en) | 2010-07-15 | 2012-01-19 | The Schepens Eye Research Institute, Inc. | Compositions and methods of treatment of corneal endothelium disorders |
| CN102079772A (zh) | 2010-12-09 | 2011-06-01 | 中国药科大学 | 一类五环三萜-13,28-内酯化合物、其制备方法和用途 |
| CN102070697A (zh) | 2010-12-09 | 2011-05-25 | 中国药科大学 | 一种齐墩果酸衍生物、其制备方法及用途 |
| RS56795B1 (sr) | 2010-12-17 | 2018-04-30 | Reata Pharmaceuticals Inc | Pirazolil i pirimidinil triciklični enoni kao antioksidantni modulatori inflamacije |
| US8846647B2 (en) | 2011-01-31 | 2014-09-30 | Bristol-Myers Squibb Company | C-17 and C-3 modified triterpenoids with HIV maturation inhibitory activity |
| CN102093462B (zh) | 2011-02-28 | 2012-11-21 | 贵州省中国科学院天然产物化学重点实验室 | 1α,2α-二羟基齐墩果酸的制备方法和应用 |
| CN102153613B (zh) | 2011-02-28 | 2013-08-14 | 贵州省中国科学院天然产物化学重点实验室 | 夏枯草酸的制备方法和应用 |
| EP2683731B1 (en) * | 2011-03-11 | 2019-04-24 | Reata Pharmaceuticals, Inc. | C4-monomethyl triterpenoid derivatives and methods of use thereof |
| WO2012154554A1 (en) | 2011-05-06 | 2012-11-15 | Catabasis Pharmaceuticals, Inc. | Fatty acid triterpene derivatives and their uses |
| CN102250189B (zh) | 2011-05-20 | 2012-08-29 | 中国药科大学 | 一种具有1,12-二烯-3-酮骨架的甘草次酸衍生物、其制备方法及医药用途 |
| TW201348245A (zh) | 2012-04-27 | 2013-12-01 | Reata Pharmaceuticals Inc | 齊墩果酸（ｂａｒｄｏｘｏｌｏｎｅ ｍｅｔｈｙｌ）之２，２－二氟基丙醯胺衍生物、多晶型及其使用方法 |
| WO2013169740A2 (en) | 2012-05-08 | 2013-11-14 | Trustees Of Dartmouth College | Synthetic triterpenoids and methods for modulating stem/progenitor cell gene expression |
| US8981144B2 (en) | 2012-05-08 | 2015-03-17 | Trustees Of Dartmouth College | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof |
| US8921419B2 (en) | 2012-05-08 | 2014-12-30 | Trustees Of Dartmouth College | Triterpenoids and compositions containing the same |
| WO2013188818A1 (en) * | 2012-06-15 | 2013-12-19 | Reata Pharmaceuticals, Inc. | A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof |
| RU2487884C1 (ru) | 2012-07-13 | 2013-07-20 | Общество с ограниченной ответственностью "Дакор" (ООО "Дакор") | Средство, обладающее антиоксидантной, противовоспалительной, нейропротекторной, гиполипидемической, гипохолестеринемической, гипогликемической, гепатопротекторной, иммуносупрессорной активностями |
| CN103665087A (zh) | 2012-09-03 | 2014-03-26 | 上海源力生物技术有限公司 | 一种萜类化合物及其在医药上的应用 |
| JP2015527407A (ja) | 2012-09-10 | 2015-09-17 | アッヴィ・インコーポレイテッド | グリチルレチン酸誘導体およびその使用方法 |
| US9512094B2 (en) | 2012-09-10 | 2016-12-06 | Reata Pharmaceuticals, Inc. | C17-heteroaryl derivatives of oleanolic acid and methods of use thereof |
| US9278912B2 (en) | 2012-09-10 | 2016-03-08 | Reata Pharmaceuticals, Inc. | C13-hydroxy derivatives of oleanolic acid and methods of use thereof |
| SMT201700501T1 (it) | 2012-09-10 | 2017-11-15 | Reata Pharmaceuticals Inc | Derivati c17-eteroarilici dell'acido oleanolico e metodi d'uso degli stessi |
| MX366913B (es) | 2012-09-10 | 2019-07-30 | Reata Pharmaceuticals Inc | Derivados de c17-alcanodiilo y alquenodiilo de ácido oleanólico y métodos de uso de los mismos. |
| JP5972986B2 (ja) | 2012-09-28 | 2016-08-17 | アプライド ファーマシューティカル サイエンス インコーポレイテッド | Ｃｄｄｏエチルエステルの多形体及びその用途 |
| CN102875634B (zh) | 2012-10-24 | 2014-08-20 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯的几种晶型 |
| CN102887936A (zh) | 2012-10-24 | 2013-01-23 | 苏州晶云药物科技有限公司 | 2-氰基-3,12-二氧代齐墩果-1,9(11)-二烯-28-酸甲酯晶型 |
| UY39092A (es) | 2013-04-24 | 2021-03-26 | Abbvie Inc | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso |
| MY198522A (en) | 2013-08-23 | 2023-09-04 | Reata Pharmaceuticals Inc | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof |
| CA2936550C (en) | 2014-01-24 | 2022-07-26 | Abbvie Inc. | Aryl and arylalkyl substituted pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators |
| WO2016130927A1 (en) | 2015-02-12 | 2016-08-18 | Reata Pharmaceuticals, Inc. | Imidazolyl tricyclic enones as antioxidant iflammation modulators |
| JP7074674B2 (ja) | 2015-09-23 | 2022-05-24 | リアタ ファーマシューティカルズ インコーポレイテッド | Ｉｌ－１７の阻害及び他の使用のためのｃ４修飾オレアノール酸誘導体 |
| US10953020B2 (en) | 2016-11-08 | 2021-03-23 | Reata Pharmaceuticals, Inc. | Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof |
| TWI831738B (zh) | 2016-12-16 | 2024-02-11 | 美商瑞塔醫藥有限責任公司 | 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物 |
-
2013
- 2013-04-24 TW TW102114730A patent/TW201348245A/zh unknown
- 2013-04-24 NZ NZ630222A patent/NZ630222A/en unknown
- 2013-04-24 UY UY0001034764A patent/UY34764A/es active IP Right Grant
- 2013-04-24 CN CN201380034275.0A patent/CN104395332B/zh active Active
- 2013-04-24 MY MYPI2014003024A patent/MY172750A/en unknown
- 2013-04-24 PL PL17175885T patent/PL3444261T3/pl unknown
- 2013-04-24 HU HUE17175885A patent/HUE053113T2/hu unknown
- 2013-04-24 EA EA201491972A patent/EA030468B1/ru unknown
- 2013-04-24 LT LTEP17175885.7T patent/LT3444261T/lt unknown
- 2013-04-24 HU HUE13720708A patent/HUE035673T2/en unknown
- 2013-04-24 PT PT137207080T patent/PT2841445T/pt unknown
- 2013-04-24 BR BR112014026640-9A patent/BR112014026640B1/pt active IP Right Grant
- 2013-04-24 WO PCT/US2013/038064 patent/WO2013163344A1/en not_active Ceased
- 2013-04-24 SI SI201331856T patent/SI3444261T1/sl unknown
- 2013-04-24 EP EP17175885.7A patent/EP3444261B1/en active Active
- 2013-04-24 RS RS20170770A patent/RS56154B1/sr unknown
- 2013-04-24 HK HK15107525.2A patent/HK1207085A1/xx unknown
- 2013-04-24 DK DK13720708.0T patent/DK2841445T3/en active
- 2013-04-24 RS RS20210286A patent/RS61544B1/sr unknown
- 2013-04-24 AU AU2013251602A patent/AU2013251602B2/en active Active
- 2013-04-24 ES ES17175885T patent/ES2861393T3/es active Active
- 2013-04-24 SM SM20210166T patent/SMT202100166T1/it unknown
- 2013-04-24 PL PL13720708T patent/PL2841445T3/pl unknown
- 2013-04-24 SM SM20170396T patent/SMT201700396T1/it unknown
- 2013-04-24 PT PT171758857T patent/PT3444261T/pt unknown
- 2013-04-24 ES ES13720708.0T patent/ES2634315T3/es active Active
- 2013-04-24 TW TW106112410A patent/TWI623548B/zh active
- 2013-04-24 MX MX2018007876A patent/MX387999B/es unknown
- 2013-04-24 CA CA2869783A patent/CA2869783C/en active Active
- 2013-04-24 KR KR1020147032968A patent/KR102101774B1/ko active Active
- 2013-04-24 DK DK17175885.7T patent/DK3444261T3/da active
- 2013-04-24 US US13/869,833 patent/US8993640B2/en active Active
- 2013-04-24 SI SI201330749T patent/SI2841445T1/sl unknown
- 2013-04-24 SG SG11201406868XA patent/SG11201406868XA/en unknown
- 2013-04-24 AR ARP130101383A patent/AR092823A1/es not_active Application Discontinuation
- 2013-04-24 MX MX2014013076A patent/MX357060B/es active IP Right Grant
- 2013-04-24 HR HRP20171275TT patent/HRP20171275T1/hr unknown
- 2013-04-24 LT LTEP13720708.0T patent/LT2841445T/lt unknown
- 2013-04-24 UA UAA201412683A patent/UA116209C2/uk unknown
- 2013-04-24 ME MEP-2017-178A patent/ME02926B/me unknown
- 2013-04-24 EP EP13720708.0A patent/EP2841445B1/en active Active
- 2013-04-24 JP JP2015509119A patent/JP6410710B2/ja active Active
- 2013-04-24 PE PE2014001894A patent/PE20150160A1/es active IP Right Grant
-
2014
- 2014-10-09 ZA ZA2014/07326A patent/ZA201407326B/en unknown
- 2014-10-21 DO DO2014000236A patent/DOP2014000236A/es unknown
- 2014-10-22 IL IL235275A patent/IL235275B/en active IP Right Grant
- 2014-10-24 CL CL2014002886A patent/CL2014002886A1/es unknown
- 2014-10-29 CO CO14240045A patent/CO7170182A2/es unknown
-
2015
- 2015-02-19 US US14/625,829 patent/US9701709B2/en active Active
-
2017
- 2017-06-14 US US15/622,568 patent/US11078230B2/en active Active
- 2017-09-12 CY CY20171100959T patent/CY1119333T1/el unknown
-
2018
- 2018-09-25 JP JP2018178470A patent/JP6637136B2/ja active Active
-
2021
- 2021-03-26 CY CY20211100266T patent/CY1124130T1/el unknown
- 2021-06-25 US US17/304,778 patent/US12065464B2/en active Active
-
2024
- 2024-04-17 FR FR24C1015C patent/FR24C1015I2/fr active Active
- 2024-04-17 LT LTPA2024511C patent/LTC2841445I2/lt unknown
- 2024-04-18 FI FIC20240012C patent/FIC20240012I1/fi unknown
- 2024-04-18 HU HUS2400010C patent/HUS2400010I1/hu unknown
- 2024-04-25 CY CY2024012C patent/CY2024012I1/el unknown
- 2024-05-29 NL NL301276C patent/NL301276I2/nl unknown
- 2024-07-09 US US18/767,855 patent/US20250051388A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO7170182A2 (es) | Derivados de 2,2-difluoropropinamida de bardoxolona metilo, formas polimórficas y métodos de uso de los mismos | |
| ECSP23088864A (es) | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso | |
| MX355428B (es) | Formas cristalinas del acido [ (4-hidroxi-1-metil-7-fenoxi-isoquin olin-3-carbonil) -amino] -acetico inhibidor de prolil hidroxilasa. | |
| DOP2019000290A (es) | Inhibidores de quinasa y usos de los mismos | |
| SV2017005487A (es) | Derivados de 4h-pirrol[3,2-c]piridin-4-ona | |
| CR11623A (es) | Compuestos | |
| GT201400017A (es) | Derivados de piridin-2 (1h) -ona como inhibidores de jak | |
| CL2009001686A1 (es) | Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados. | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| CL2017000540A1 (es) | Formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)oxi)-n,2-dimetilbenzofuran-3-carboxamida. | |
| ECSP13012914A (es) | Síntesis de derivados de 2-carboxamida-cicloamino-urea | |
| AR080203A1 (es) | Formas solidas que comprenden una ciclopropilamida | |
| BR112015022509A2 (pt) | forma cristalina de cis-(e)-4-(3-fluorofenil)-2',3',4',9'-tetra-hidro-n,n-dimetil-2'-(1-oxo-3-fenil-2-propenil)-espiro[ciclohexano-1,1'[1h]-pirido[3,4-b]indol]-4-amina cristalina | |
| MX2013007504A (es) | Composiciones y metodos de uso de formas cristalinas de analogos de wortmanina. | |
| BR112015030589A8 (pt) | formas polimórficas de fosfato de icotinibe, composição farmacêutica compreendendo as referidas formas e usos das mesmas | |
| AR124675A2 (es) | Derivados de 2,2-difluoropropanamida y metil bardoxolona, formas polimórficas y métodos de uso | |
| UY35347A (es) | Formas cristalinas de un inhibidor de la prolil hidroxilasa | |
| CU20100228A7 (es) | Nuevos derivados de ácido l-glutámico y l-glutamina marcados con [f-18] (1), su uso y procedimiento para su preparación |